162 related articles for article (PubMed ID: 34636513)
21. Bioavailability, Pharmacokinetics, and Transepidermal Water Loss of Short Contact Tazarotene Lotion 0.1% Versus Tazarotene (Tazorac
Sidgiddi S; Allenby K; Okumu F; Gautam A
J Clin Aesthet Dermatol; 2019 Sep; 12(9):16-24. PubMed ID: 31641413
[No Abstract] [Full Text] [Related]
22. Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis.
Kircik LH; Papp KA; Stein Gold L; Harris S; Pharm TL; Pillai R
J Drugs Dermatol; 2019 Mar; 18(3):279-284.. PubMed ID: 30909333
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Tazarotene Lotion, 0.045% in the Treatment of Truncal Acne Vulgaris.
Kircik L
J Drugs Dermatol; 2022 Jul; 21(7):713-716. PubMed ID: 35816073
[TBL] [Abstract][Full Text] [Related]
24. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
25. Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris.
Tanghetti E; Dhawan S; Torok H; Kircik L
Dermatol Online J; 2007 Jul; 13(3):1. PubMed ID: 18328195
[TBL] [Abstract][Full Text] [Related]
26. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris.
Pariser D; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s18-23. PubMed ID: 18575222
[TBL] [Abstract][Full Text] [Related]
27. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology.
Tanghetti EA; Stein Gold L; Del Rosso JQ; Lin T; Angel A; Pillai R
J Dermatolog Treat; 2021 Jun; 32(4):391-398. PubMed ID: 31522563
[TBL] [Abstract][Full Text] [Related]
28. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
Shalita AR; Berson DS; Thiboutot DM; Leyden JJ; Parizadeh D; Sefton J; Walker PS; Gibson JR;
Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
[TBL] [Abstract][Full Text] [Related]
29. Tazarotene 0.045% Lotion: A Novel Retinoid Formulation.
Mohney LA; Singh R; Feldman SR
Ann Pharmacother; 2022 Oct; 56(10):1174-1180. PubMed ID: 35112585
[TBL] [Abstract][Full Text] [Related]
30. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
Tanghetti E; Dhawan S; Green L; Ling M; Downie J; Germain MA; Kasteler JS; Kircik L; Oefelein MG; Draelos Z
J Drugs Dermatol; 2011 Jul; 10(7):783-92. PubMed ID: 21720661
[TBL] [Abstract][Full Text] [Related]
31. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
32. Enhanced Skin Deposition of Betamethasone Dipropionate from a Novel Formulation and Drug Delivery Technology.
Draelos ZD; Draelos MM; Steele F; Georgiou M; Praestegaard M
Dermatol Ther (Heidelb); 2023 Aug; 13(8):1763-1771. PubMed ID: 37351830
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
Sugarman JL; Weiss J; Tanghetti EA; Bagel J; Yamauchi PS; Stein Gold L; Lin T; Martin G; Pillai R; Israel R
J Drugs Dermatol; 2018 Aug; 17(8):855-861. PubMed ID: 30124724
[TBL] [Abstract][Full Text] [Related]
34. Development of a simple method for simultaneous determination of tazarotene and betamethasone dipropionate and their metabolites using LC-MS method and its application to dermatopharmacokinetic study.
Li L; Zhang M; Ma P; Qian K
Biomed Chromatogr; 2019 Aug; 33(8):e4557. PubMed ID: 30990899
[TBL] [Abstract][Full Text] [Related]
35. Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.
Stein Gold L; Elewski B; Draelos Z; Jacobson A; Lin T
J Drugs Dermatol; 2020 May; 19(5):504-514. PubMed ID: 32484629
[TBL] [Abstract][Full Text] [Related]
36. Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential.
Del Rosso JQ; Kircik L; Lin T; Pillai R
J Clin Aesthet Dermatol; 2019 Jan; 12(1):11-15. PubMed ID: 30881571
[No Abstract] [Full Text] [Related]
37. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis.
Tang-Liu DD; Matsumoto RM; Usansky JI
Clin Pharmacokinet; 1999 Oct; 37(4):273-87. PubMed ID: 10554045
[TBL] [Abstract][Full Text] [Related]
38. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Feldman SR; Werner CP; Alió Saenz AB
J Drugs Dermatol; 2013 Apr; 12(4):438-46. PubMed ID: 23652892
[TBL] [Abstract][Full Text] [Related]
39. Demonstration of the biphasic release of 0.1% halcinonide cream.
Draelos ZD
J Drugs Dermatol; 2015 Jan; 14(1):89-90. PubMed ID: 25607913
[TBL] [Abstract][Full Text] [Related]
40. Topical tazarotene cream (0.1%) in the treatment of facial acne: an open clinical trial.
Zakaria AS; Paul HK; Rahman MA; Islam MT; Choudhury AM
Bangladesh Med Res Counc Bull; 2010 Aug; 36(2):43-6. PubMed ID: 21473199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
